HAWC Research Partners
mRNA Vaccines
At Queen's University Belfast, the HAWC technology is being used for the development of a cancer vaccine for osteosarcoma. Osteosarcoma is the most frequently occurring, primary bone cancer worldwide, affecting approximately 3–4 individuals per million annually among children and adolescents. The Queen's team is applying a bespoke machine learning algorithm to develop a multi-epitope mRNA vaccine. XapHe is supporting with the manufacture of HAWC/mRNA nanoparticles.
Advanced Wound healing
The DCU team has produced a polymeric nano gel for advanced wound healing that contains a microRNA therapy. The miRs are designed to target each phase of wound healing. The three miRs are complexed with HAWC, lyophilised, and formulated within the nano gel. Results in vivo have exceeded commercial products to date.
Treatments for Ocular Diseases
Collaborators at Birmingham have identified the therapeutic value of a new mRNA which needs to be delivered to both the front and back of the eye using a drop formulation. XapHe is providing the HAWC nanoparticles which have surpassed all expectations in terms of delivery to the target site.